Full-Time

Administrative Coordinator

Fortrea

Fortrea

10,001+ employees

Global CRO providing Phase I-IV trials

No salary listed

Leeds, UK

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Microsoft Office
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Fortrea

See people who can refer or advise you

Requirements
  • Typically 3+ years of administrative experience.
  • High attention to detail and follow-through.
  • Strong organizational and multitasking skills.
  • Ability to liaise with multiple teams and manage communication flow across several projects simultaneously.
  • Working knowledge of Microsoft Office, including Outlook, Word, and Excel.
Responsibilities
  • Support the Clinical Operations team in participant recruitment efforts and ensure participant eligibility for the appropriate clinical trial.
  • Prepare and collate health screening data from different teams and communicate it to physicians, pathologists, study managers, and other appropriate groups for subject selection.
  • Gather and present participants' laboratory results and collate screening data for physician medical review and subject acceptance.
  • Determine the panel of eligible and standby subjects for specific studies after receiving completed physician data.
  • Conduct daily quality control of screening Case Report Forms.
  • Organize, oversee, and compile Case Report Form workbooks; manage subject identification codes and information associated with Case Report Forms and Informed Consent Forms; and maintain post-screening data archives.
  • Maintain ethical and medical confidentiality and ensure volunteer records are stored securely with restricted access.
  • Maximize clinic screening capacity and the number of participants checking in daily.
  • Coordinate the subject callback process and communicate with participants.
Desired Qualifications
  • Experience in clinical trials, laboratory, hospital, or a similar setting.

Fortrea is a global contract research organization that provides clinical development services for the life sciences industry. It offers full service, functional service, and hybrid outsourcing models across Phase I–IV trials, clinical pharmacology, and consulting, serving biotech, biopharma, medical devices, and diagnostics. Its work is delivered through a network of investigators and specialized teams in approximately 100 countries, supporting trial design, execution, data management, and regulatory compliance. Fortrea’s approach combines its legacy experience from Covance and Labcorp with a pureplay CRO model to deliver fit-for-purpose solutions and agile project delivery. This positions it to manage trials across more than 20 therapeutic areas with scientific rigor and operational excellence. The company aims to bring predictability to clinical trial execution and help clients turn research ideas into real-world outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

2023

Get referred to Fortrea

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $678.2 million, beating expectations and lifting guidance.
  • Fortrea raised 2026 revenue guidance to $2.55 billion-$2.65 billion in July 2026.
  • Cost optimization targets of $70-80 million gross support margin recovery in 2026.

What critics are saying

  • The 2025 shareholder class action remains active after Fortrea's January 2026 dismissal motion.
  • Ongoing 2024 and 2025 restructuring through 2026 signals continued redundant-position eliminations.
  • Revenue still declined 4.5% in Q2 2026, exposing weak underlying growth.

What makes Fortrea unique

  • Fortrea's July 2026 book-to-bill stayed 1.12x, signaling durable demand.
  • September 2026 Worldwide early-phase acquisition adds Austin, San Antonio, and Pflugerville capacity.
  • Integrated Phases I-IV platform now spans first-in-human studies through post-approval evidence generation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

27%

1 year growth

27%

2 year growth

27%
Clinical Trial Vanguard
Sep 3rd, 2026
Fortrea’s $45M Early-Phase Acquisition Will Reshape Your Phase I Startup Timeline, Are You Ready?

Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division adds a 60,000 sq ft bioanalytical lab. Here's what it means for Phase I site…

GlobeNewswire
Sep 3rd, 2026
Fortrea acquires the clinical pharmacology unit and bioanalytical laboratory activities of Worldwide Clinical Trials.

Fortrea acquires the clinical pharmacology unit and bioanalytical laboratory activities of Worldwide Clinical Trials. This acquisition brings dedicated bioanalytical expertise and increased capacity to Fortrea's early clinical development network as Worldwide continues its strategy to strengthen its clinical development activities, therapeutic leadership, and presence in high-growth markets.

Australian Associated Press
Sep 2nd, 2026
Fortrea to acquire clinical pharmacology unit and bioanalytical laboratory operations from Worldwide Clinical Trials.

Fortrea to acquire clinical pharmacology unit and bioanalytical laboratory operations from Worldwide Clinical Trials. September 02, 2026 Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Highlights * Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials * Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas * Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea's ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies * Strengthens Fortrea's end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence generation * Supports Fortrea's growth strategy through expanded scientific capabilities, increased early clinical development capacity and enhanced ability to create long-term value for shareholders * Supports Worldwide Clinical Trials' existing rapid global growth across oncology, neuroscience, internal medicine, and rare disease

Yahoo Finance
Aug 15th, 2026
Fortrea shares fall 5.7% despite Q2 revenue beat of $678M in drug development sector review

Fortrea, a contract research organisation spun off from Labcorp in 2023, reported Q2 revenues of $678.2 million, down 4.5% year-on-year but exceeding analyst expectations by 4.7%. The company helps pharmaceutical, biotech, and medical device companies develop products through clinical trials and support services. Chief executive officer Anshul Thakral said the results reflected continued progress against the company's strategy and disciplined execution. The quarter saw Fortrea beat earnings per share estimates, with full-year revenue guidance surpassing analyst expectations. Among the eight drug development inputs and services stocks tracked, revenues collectively beat consensus estimates by 4.1%. Despite posting the slowest revenue growth in the group, the sector's share prices rose 12.6% on average. Fortrea's stock fell 5.7% following the results and currently trades at $19.52.

Yahoo Finance
Jul 29th, 2026
Fortrea beats Q2 revenue estimates despite 4.5% decline, raises full-year guidance to $2.66B

Fortrea Holdings reported second-quarter revenue of $678.2 million, exceeding analyst estimates by 4.7% despite a 4.5% year-on-year decline. The clinical research company's adjusted earnings per share of $0.23 beat consensus estimates by 27.2%. The company raised its full-year revenue guidance to $2.66 billion at the midpoint, up 2.1% from previous guidance and 1.8% above analyst expectations. Full-year EBITDA guidance of $212.5 million also surpassed estimates. Operating margin improved significantly to 2.2%, compared to negative 46.5% in the same quarter last year. CEO Anshul Thakral said the results reflect continued progress against the company's strategy. However, analysts project revenue to remain flat over the next 12 months, suggesting limited near-term growth prospects.